Profile data is unavailable for this security.
About the company
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
- Revenue in USD (TTM)6.85m
- Net income in USD-138.42m
- Incorporated2020
- Employees77.00
- LocationCentessa Pharmaceuticals PLC3Rd Floor, 1 Ashley RoadALTRINCHAM WA14 2DTUnited KingdomGBR
- Websitehttps://www.centessa.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perspective Therapeutics Inc | -304.00k | -48.91m | 886.67m | 116.00 | -- | -- | -- | -- | -0.1622 | -0.197 | -0.0009 | -- | -- | -- | -- | -2,620.69 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| OPKO Health Inc | 799.60m | -252.43m | 892.15m | 3.93k | -- | 0.7122 | -- | 1.12 | -0.3427 | -0.3427 | 1.08 | 1.80 | 0.3859 | 7.53 | 6.87 | 203,461.30 | -12.18 | -7.14 | -13.58 | -8.14 | 32.63 | 34.42 | -31.56 | -13.83 | 1.58 | -4.96 | 0.2217 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
| Tyra Biosciences Inc | 0.00 | -75.45m | 893.18m | 49.00 | -- | 2.29 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Ocular Therapeutix Inc | 59.84m | -115.27m | 898.36m | 267.00 | -- | 2.20 | -- | 15.01 | -1.09 | -1.09 | 0.6335 | 2.64 | 0.1793 | 2.23 | 2.51 | 224,127.30 | -34.54 | -46.70 | -37.58 | -54.18 | 90.99 | 89.36 | -192.62 | -228.65 | 21.29 | -9.10 | 0.1401 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 899.64m | 284.00 | -- | 4.42 | -- | 11.12 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| USANA Health Sciences, Inc. | 900.45m | 61.94m | 911.00m | 1.80k | 14.93 | 1.82 | 12.22 | 1.01 | 3.20 | 3.20 | 46.56 | 26.25 | 1.46 | 2.73 | -- | 500,250.00 | 10.03 | 16.23 | 12.49 | 21.75 | 80.98 | 81.42 | 6.88 | 8.96 | 3.20 | -- | 0.0026 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 926.54m | 309.00 | -- | 1.24 | -- | 26.23 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Centessa Pharmaceuticals PLC - ADR | 6.85m | -138.42m | 943.92m | 77.00 | -- | 3.90 | -- | 137.74 | -1.42 | -1.42 | 0.0704 | 2.14 | 0.0187 | -- | 0.2263 | 90,171.05 | -37.82 | -- | -41.02 | -- | -- | -- | -2,019.80 | -- | -- | -- | 0.263 | -- | -- | -- | 30.12 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 963.28m | 267.00 | -- | -- | -- | 2.33 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Liquidia Corp | 15.97m | -107.69m | 980.75m | 136.00 | -- | 11.36 | -- | 61.42 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Innoviva Inc | 311.59m | 181.39m | 986.00m | 112.00 | 7.21 | 1.41 | 4.49 | 3.16 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 1.00bn | 284.00 | -- | -- | -- | 24.14 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 31 Mar 2024 | 5.62m | 5.60% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 3.08m | 3.07% |
| First Light Asset Management LLCas of 31 Mar 2024 | 3.00m | 2.99% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.96m | 2.95% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.79m | 2.78% |
| Point72 Asset Management LPas of 31 Mar 2024 | 2.26m | 2.25% |
| Adage Capital Management LPas of 31 Mar 2024 | 2.25m | 2.24% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.13m | 2.13% |
| Octagon Capital Advisors LPas of 31 Mar 2024 | 2.06m | 2.05% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 1.41m | 1.41% |
